Mass General Brigham has launched a new AI company called AIwithCare, which focuses on improving the accuracy and efficiency of clinical trial patient matching. This spinout commercializes an advanced AI tool named RECTIFIER (RAG-Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review) developed by Mass General Brigham researchers. RECTIFIER uses generative AI techniques to analyze electronic health records (EHR) and clinical notes to quickly and effectively determine patient eligibility criteria for clinical trials.
The AI tool significantly outperforms traditional manual screening methods, speeding up patient identification and enrollment processes for trials, such as those for heart failure. By automating the screening procedure, AIwithCare’s technology enhances both the precision and scale of matching patients to appropriate studies, which has historically been a bottleneck in clinical research. This advancement can accelerate trial timelines and strengthen recruitment diversity by leveraging richer data insights from EHR.
Mass General Brigham’s spinout reflects a growing trend in healthcare to harness AI for optimizing clinical trial workflows, ultimately advancing medical innovation. The strategic creation of AIwithCare aims to bring this cutting-edge technology to broader adoption beyond the original research setting, illustrating the potential for AI to transform how medical trials are conducted and how patients access new treatments.
